Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998277 | 1.00 | TSHR (0.48) | TSHRSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL13736171 | 1.00 | TSHR (0.48) | TSHRSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL20840269 | 1.00 | TSHR (0.48) | TSHRSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL4173227 | 0.96 | TSHR (0.52) | TSHRSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL19437533 | 0.90 | TSHR (0.45) | TSHRSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL31664097 | 0.85 | TSHR (0.55) | TSHRSMN1; SMN2ALDH1A1L3MBTL1TAAR1 | |
| SCHEMBL22775016 | 0.85 | SMN1; SMN2 (0.41) | TSHRSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL21643789 | 0.85 | SMN1; SMN2 (0.41) | TSHRSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL26923902 | 0.85 | TSHR (0.58) | TSHRSMN1; SMN2ALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL26689560 | 0.84 | TSHR (0.40) | TSHRSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020018788-A1 | DEGRADERS THAT TARGET PROTEINS VIA KEAP1 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-01-23 | — | — | WO | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-10017527-B2 | KLK4 inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2018-07-10 | — | — | US | disclosed |
| US-20170101427-A1 | NOVEL KLK4 INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2017-04-13 | — | — | US | disclosed |
| EP-3122758-A1 | NOVEL KLK4 INHIBITORS | Universiteit Antwerpen (BE) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015144933-A1 | NOVEL KLK4 INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2015-10-01 | — | — | WO | disclosed |
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2014-03-20 | — | — | US | disclosed |
| EP-2707034-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | Universiteit Antwerpen (BE) | 2014-03-19 | — | — | EP | disclosed |
| WO-2012152807-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017527-B2 | KLK4 inhibitors | KLK4, KLK3, KLK1 | TSHR 3699/4885SMN1; SMN2 4157/4885MEN1 3183/4885 |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885SMN1; SMN2 2647/4885MEN1 4055/4885 |
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885SMN1; SMN2 2647/4885MEN1 4055/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885SMN1; SMN2 2647/4885MEN1 4055/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885SMN1; SMN2 2647/4885MEN1 4055/4885 |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, USP2, MYCBP2 | TSHR 4025/4885SMN1; SMN2 2413/4885MEN1 2951/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | TSHR 3114/4885SMN1; SMN2 737/4885MEN1 2692/4885 |
| US-12168057-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885SMN1; SMN2 2647/4885MEN1 4055/4885 |
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | PLAU, SERPINE1, PRSS3 | TSHR 1872/4885SMN1; SMN2 4493/4885MEN1 2509/4885 |
| US-20170101427-A1 | NOVEL KLK4 INHIBITORS | KLK4, KLK3, KLK1 | TSHR 3647/4885SMN1; SMN2 4263/4885MEN1 3716/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885SMN1; SMN2 2647/4885MEN1 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.